Welcome to the Technology Networks Research Store, leading strategic market analysis for the Biotech and Healthcare sector from the most trusted sources in the world. You can browse through the portfolio of reports below or enter keywords in the search box to find the information you have been looking for.
  • Browse Reports & Briefs
  • Browse Company Profiles
  • Browse Industry Profiles
  • Latest News
Number of Employees

< 250 (30)

250 - 999 (22)

1,000 - 2,499 (20)

2,500 - 4,999 (32)

5,000 - 9,999 (59)

10,000 - 49,999 (121)

50,000+ (45)

Annual Revenue US$m

< 50 (19)

50 - 99 (7)

100 - 199 (8)

200 - 499 (21)

500 - 999 (13)

1,000 - 1,999 (48)

2,000+ (201)

Top stories

Insys signs sub-license agreement with Gold Coast for treatment of CP/CPPS

Insys Therapeutics, Inc., a specialty pharmaceutical company, has signed an exclusive sub-license agreement with Gold Coast Therapeutics, to develop a combination of Cromolyn Sodium and Cetirizine as a new chemical entity for the treatment of chronic prostatitis/chronic pelvic pain syndrome, or CP/CPPS...more >>

Glenmark announces approval and launch of oral contraceptive tablets in US

Glenmark Generics Inc., USA, the subsidiary of Glenmark Generics Limited, has announced the US market approval and launch of Ashlyna extended-cycle oral contraceptive tablets...more >>

Jubilant's ANDA for hypertension and allergy drugs receives FDA approval

Jubilant Life Sciences Ltd has received FDA approval for abbreviated new drug application, or ANDA, of Irbesartan Tablets USP, 75mg, 150mg, and 300mg and Cetirizine Hydrochloride Tablets Chewable, 5mg and 10mg...more >>

Curis Q4 net loss up

Curis, Inc., a biotechnology company, has reported that net loss for the fourth quarter ended December 31, 2014 was $5.69 million, or $0.07 loss per share, compared to a net loss of $4.2 million, or $0.05 loss per share, for the same quarter ended December 31, 2013...more >>